Research on the biomarkers for the prediction of efficacy in first-line chemotherapy of metastatic colorectal cancer using SELDI-TOF-MS

doi:10.3877/cma.j.issn.2095-3224.2013.02.05

Abstract

Abstract:

Objective

To identify serum protein patterns which could predict the efficacy of first-line chemotherapy of metastatic colorectal cancer(CRC).

Methods

Serum from 70 patients diagnosed as metastatic colorectal cancer before first-line chemotherapy were collected and analyzed for protein patterns using ANN analysis of SELDI-TOF-MS.Among the 70 cases, 44 patients received FOLFOX regimen, while the other 26 patients received FOLFIRI regimen.After four cycles of the treatment, RECIST criteria were used to define the responders(R)and non-responders(NR).

Results

With the method of SELDI-TOF-MS, 10 protein peaks were identified to be significantly high expressed in 42 responders than in those 28 non-responders.A prediction model was constructed by the combination of these 10 peaks, which could achieve an accuracy of 90.0%(63/70)for the chemotherapy efficiency of CRC patients.

Conclusions

The prediction model combined of 10 protein peaks could be helpful for prediction of the first-line chemotherapy efficiency of metastatic CRC patients.

Key words: Biological markers, Colorectal neoplasms, Protein array analysis

Hong SHEN, Ying YUAN, Jing-jing LI, Xue-feng FANG, Chun-wen TAN, Jie-kai YU, Shu ZHENG. Research on the biomarkers for the prediction of efficacy in first-line chemotherapy of metastatic colorectal cancer using SELDI-TOF-MS[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2013, 02(02): 68-71.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2013.02.05

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2013/V02/I02/68

Figures/Tables 2

References 16

[1]	Rougier P，Van Cutsem E，Bajetta E，et al.Randomized trial of irinotecan versus fuorouracil by continuous infusion after fuorouracil failure in patients with metastatic colorectal cancer.Lancet，1998,352(9138):1407-1412.
[2]	Saltz LB，Cox JV，Blanke C，et al.Irinotecan plus fuorouracil and leucovorin for metastatic colorectal cancer.Irinotecan Study Group.N Engl J Med，2000,343(13):905-914.
[3]	Douillard JY，Cunningham D，Roth AD，et al.Irinotecan combined with fuorouracil compared with fuorouracil alone as frst-line treatment for metastatic colorectal cancer：A multicentre randomized trial.Lancet，2000,355(9212):1041-1047.
[4]	Hochster HS，Chachoua A，Speyer J，et al.Oxaliplatin with weekly bolus fuorouracil and low- dose leucovorin as first line therapy for patients with advanced colorectal cancer.J Clin Oncol，2003,21(14):2703-2707.
[5]	Sfrbye H，Glimelius B，Berglund A，et al.Multicenter phaseⅡstudy of Nordic fuorouracil and folinic acid bolus schedule combined with oxaliplatin as first- line treatment of metastatic colorectal cancer.J Clin Oncol，2004,22(1):31-38.
[6]	Leong S，Christopherson RI，Baxt er RC.Profiling of apoptotic changes in human breast cancer cells using SELDI-TOF mass spectrometry.Cell Physiol Biochem，2007,20(5):579-590.
[7]	Gross M，Top I，Laux I，et al.Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer.Clin Cancer Res，2007,13(7):1979-1986.
[8]	Chen CD，Wang CS，Hu ang YH，et al.Overexpression of CLIC1 in human gastric carcinoma and its clinicopathological significance.Proteomics，2007,7(1):155-167.
[9]	Kong F，Nicole WC，Xiao X，et al.Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.Gynecol Oncol，2006,100(2):247-253.
[10]	Chen YD，Zheng S，Yu JK，et al.Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population.Clin Cancer Res，2004,10(24):8380-8255.
[11]	Yu JK，Chen YD，Zheng S．An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics.World J Gastroenterol，2004,10(21):3127-3131.
[12]	Zheng GX，Wang CX，Qu X，et al.Establishment of serum protein pattern for screening colorectal cancer using SELDI-TOF-MS.Exp Oncol，2006,28(4):2822-2871.
[13]	Ward DG，Suggett N，Cheng Y，et al.Identification of serum biomarkers for colon cancer by proteomic analysis.Br J Cancer，2006,94(12):1898-1905.
[14]	Liu XP，Shen J，Li ZF，et al.A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry.Cancer Invest，2006,24(8):747-753.
[15]	Smith FM，Gallagher WM，Fox E，et al.Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodalneoadjuvant therapy.Ann Surg，2007,245(2):259-266.
[16]	Liao CC，Mehta A，WardNJ.Analysis of post-operative changes in serum protein expression profiles from colorectal cancer patients by MALDI-TOF mass spectrometry：a pilot methodological study.World Journal of Surgical Oncology，2010,8:33.

疗效	例数	蛋白质峰(m/z)
疗效	例数	9268	9431	9375	9298
化疗受益者(±s)	42	548.03±502.56	337.07±357.99	356.98±362.37	586.6364±552.74
化疗无效者(±s)	28	285.67±539.61	175.51±246.79	188.60±271.01	319.779±549.16
P值	?	0.000171	0.000217	0.000315	0.000396
蛋白质峰(m/z)
4304	9352	9404	4606	9198	3963
1584.676±827.35	343.3679±360.18	388.40±465.05	333.09±603.85	1602.84±2232.48	702.11±441.07
947.1406±506.90	174.2481±244.07	213.93±378.27	175.56±389.99	710.29±1786.30	500.28±305.92
0.000707	0.000707	0.000806	0.001234	0.002673	0.044639

疗效	例数	蛋白质峰(m/z)
疗效	例数	9268	9431	9375	9298
化疗受益者(±s)	42	548.03±502.56	337.07±357.99	356.98±362.37	586.6364±552.74
化疗无效者(±s)	28	285.67±539.61	175.51±246.79	188.60±271.01	319.779±549.16
P值	?	0.000171	0.000217	0.000315	0.000396
蛋白质峰(m/z)
4304	9352	9404	4606	9198	3963
1584.676±827.35	343.3679±360.18	388.40±465.05	333.09±603.85	1602.84±2232.48	702.11±441.07
947.1406±506.90	174.2481±244.07	213.93±378.27	175.56±389.99	710.29±1786.30	500.28±305.92
0.000707	0.000707	0.000806	0.001234	0.002673	0.044639

疗效	总例数	预测受益		预测无效
疗效	总例数	例数	百分率(%)	例数	百分率(%)
?	?	?	?	?	?
受益	42	39	91	3	11
无效	28	4	9	24	89
合计	70	43	?	27	?

疗效	总例数	预测受益		预测无效
疗效	总例数	例数	百分率(%)	例数	百分率(%)
?	?	?	?	?	?
受益	42	39	91	3	11
无效	28	4	9	24	89
合计	70	43	?	27	?

Please choose a citation manager

Content to export